Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Opinion|Videos|February 27, 2026
Fred Saad, MD, highlights phase 1 study of 225Ac-PSMA-Trillium in mCRPC
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Fact checked by: Hannah Clarke
Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.
Advertisement
In this video, Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study, assessing the investigational alpha-emitting radioligand therapy 225Ac-PSMA-Trillium (BAY 3563254) in patients with metastatic castration-resistant prostate cancer (mCRPC). These results were presented at the
Saad is a professor and chief of urology at University of Montreal Hospital Center.
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
ESMO 2026: Key presentations across genitourinary oncology
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5